Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler...
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate...
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that...
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial...
Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to...
Agreement supports the identification of patients eligible for Alzheimer’s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus’ clinical ordering...
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call...
Novel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer...
The Content Innovation Engine brings together Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to systematically unlock cancer biology and accelerate the path toward clinical...